首页   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
Src/Bcr Abl

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

Src/Bcr Abl

结构式 货号 产品名称 CAS号
PD 161570 结构式
 BCP24138 PD 161570 192705-80-9
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM, respectively. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor.
Tyrphostin AG 1112 结构式
 BCP24145 Tyrphostin AG 1112 153150-84-6
Tyrphostin AG 1112 is a Bcr-Abl kinase blocker that can activate the terminal differentiation of K562 cells and the purging of Ph+ cells.
Src Kinase Inhibitor I 结构式
 BCP24909 Src Kinase Inhibitor I 179248-59-0
Src Inhibitor-1 is a potent, competitive dual site (ATP- and peptide-binding) Src kinase inhibitor (IC50 values are 44 and 88 nM for Src and Lck respectively).
Saracatinib difumarate 结构式
 BCP25711 塞卡替尼富马酸盐 893428-72-3
Saracatinib Difumarate is a tyrosine kinase inhibitor selectively targeting Src and Abl, which are commonly overexpressed in chronic myeloid leukema cells.
TPX-0046 结构式
 BCP43814 TPX-0046 TPX0046
TPX-0046 is a novel RET/SRC inhibitor with a mean IC50 of 17 nM for RETG810R in Ba/F3 cell proliferation assay.
Vodobatinib 结构式
 BCP43522 Vodobatinib 1388803-90-4
Vodobatinib, also known as K-0706, is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
Elzovantinib 结构式
 BCP40929 Elzovantinib 2271119-26-5
TPX-0022, also known as CSF1R-IN-2, is an orally bioavailable multi-targeted kinase inhibitor with a novel three-dimensional macrocyclic structure that inhibits the MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinases.
KX2-391 Mesylate 结构式
 BCP25173 KX2-391 Mesylate 1080645-95-9
Tirbanibulin, also known as KX-01 and KX2-391, is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.
TL02-59 结构式
 BCP38228 TL02-59 1315330-17-6
TL02-59 is a novel potent and selective inhibitor of the myeloid Src-family kinase Fgr, suppressing AML cell growth in vitro and in vivo.
DGY-06-116 结构式
 BCP37659 DGY-06-116 2556836-50-9
DGY-06-116 is an irreversible covalent, selective Src inhibitor.
123下一页末页共 87 条记录 1 / 9 页 
2853530910